Valuation: Cybin Inc.

Market Cap 1.33B 959M 830M 785M 711M 91.95B 1.34B 9.37B 3.6B 46.62B 3.6B 3.52B 149B P/E 2027 *
-4.98x
P/E 2028 * -6.22x
Enterprise Value 858M 616M 534M 505M 457M 59.13B 864M 6.03B 2.32B 29.98B 2.32B 2.26B 95.62B EV / Sales 2027 *
-
EV / Sales 2028 * 68.9x
Free-Float
85.52%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Cybin Inc.

1 day+2.97%
1 week+5.89%
Current month+11.56%
1 month+9.42%
3 months+208.71%
6 months+182.76%
Current year+60.39%
1 week 12.61
Extreme 12.61
13.92
1 month 11.17
Extreme 11.17
14.35
Current year 3.76
Extreme 3.76
14.35
1 year 3.76
Extreme 3.76
14.35
3 years 3.76
Extreme 3.76
28.04
5 years 3.76
Extreme 3.76
92.34
10 years 3.76
Extreme 3.76
128.44
Manager TitleAgeSince
Chief Operating Officer 37 13/10/2016
Chief Executive Officer 53 03/08/2026
Chief Executive Officer 51 02/09/2025
Director TitleAgeSince
Chairman 51 05/11/2020
Director/Board Member 37 13/10/2016
Director/Board Member 65 05/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Other

Founder

-230,940 0.3726%
08/09/26 Buy

Founder

100,000 0.1613%
08/09/26 Buy

Founder

100,000 0.1613%
Change 5-day change 1-year change 3-year change Capi.($)
-3.60%+5.89%+118.30%+4.63% 959M
-1.38%+0.20%+46.42%+96.33% 69.18B
-0.33%-1.11%+35.68%+75.26% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+1.46%+2.25%+28.84%+14.54% 25.75B
-2.20%-2.00%-1.22%-14.48% 24.29B
+4.16%+4.69%+25.89%-14.18% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.39%-4.24%-9.86%+454.94% 14.09B
Average -0.43%-1.39%+38.97%+209.69% 27.18B
Weighted average by Cap. -0.83%-1.29%+32.19%+157.72%

Financials

2027 *2028 *
Net sales - 11.07M 7.95M 6.89M 6.51M 5.9M 763M 11.15M 77.73M 29.9M 387M 29.87M 29.21M 1.23B
Net income -261M -187M -162M -153M -139M -17.97B -263M -1.83B -704M -9.11B -704M -688M -29.06B -262M -188M -163M -154M -139M -18.03B -264M -1.84B -707M -9.14B -706M -690M -29.16B
Net Debt -476M -342M -296M -280M -254M -32.82B -480M -3.34B -1.29B -16.64B -1.29B -1.26B -53.07B -571M -410M -355M -336M -304M -39.36B -575M -4.01B -1.54B -19.96B -1.54B -1.51B -63.65B
Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
100
Date Price Change Volume
15/09/26 $13.12 -3.60% 1,195,690
14/09/26 $13.61 +4.93% 1,615,568
11/09/26 $12.97 +1.01% 1,150,125
10/09/26 $12.84 -6.14% 1,750,703
09/09/26 $13.68 +10.41% 1,736,363
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.26CAD
Average target price
57.39CAD
Spread / Average Target
+214.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HELP Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!